Venetech — Venetoclax 100 mg, 60 pcs, Techno Oncology
100% original product

Venetech Tablets — Venetoclax 100 mg (60 Tablets) Techno Pharma

20347 21674 -6%

Venetech 100 mg (Venetoclax) is an innovative targeted therapy and a first-in-class selective inhibitor of the B-cell lymphoma-2 (BCL-2) protein. It works by restoring the natural process of apoptosis (programmed cell death) in cancer cells that evade death by overexpressing BCL-2. By binding to this protein, Venetoclax triggers the rapid destruction of tumor cells.

Manufacturer: Techno Oncology (Techno Pharma Ltd. FZE LLC). This medicinal product is a high-quality generic of the reference drug Venclexta, produced in strict accordance with international Good Manufacturing Practice (GMP) standards. It has demonstrated bioequivalence and comparable therapeutic efficacy to the original brand.

Key Features:

  • Mechanism: Direct induction of apoptosis by inhibiting the anti-apoptotic protein BCL-2.
  • Selective Action: Specifically targets malignant cells with minimal impact on healthy tissues.
  • Clinical Efficacy: Effective even in high-risk patients, including those with 17p deletion chromosomal abnormalities.

Venetech is indicated for the treatment of adult patients with:

  • 🔹 Chronic Lymphocytic Leukemia (CLL).
  • 🔹 Small Lymphocytic Lymphoma (SLL).
  • 🔹 Acute Myeloid Leukemia (AML) — in combination with azacitidine, decitabine, or low-dose cytarabine.

Sales Unit: 1 bottle containing 60 tablets of 100 mg Venetoclax.

⚠️ APPLICATION INSTRUCTIONS:

  • Ramp-up Schedule: Requires a 5-week dose titration (starting from 20 mg up to the maintenance dose of 400 mg) to mitigate the risk of Tumor Lysis Syndrome (TLS).
  • Administration: Take once daily with a meal at approximately the same time. Tablets must be swallowed whole.
  • Dietary Restrictions: Avoid grapefruit, Seville oranges, and starfruit during treatment, as they significantly affect drug metabolism.
  • Storage: Store in a dry place below 30°C, protected from direct sunlight.

  • Drug Interactions: Concurrent use of strong CYP3A inhibitors is contraindicated during the initiation and ramp-up phase.
  • Pregnancy: Highly hazardous to the fetus; effective contraception is mandatory.
  • Hypersensitivity to Venetoclax or any excipients.
  • Pediatric use (safety and efficacy not established in children).

Treatment must be supervised by a healthcare professional. Potential side effects include:

  • 🧪 Tumor Lysis Syndrome (TLS): A serious metabolic risk requiring monitoring and prophylaxis.
  • 🩸 Hematologic: Neutropenia, anemia, and thrombocytopenia.
  • 🤢 Gastrointestinal: Diarrhea, nausea, and vomiting.
  • 🤒 General: Fatigue and increased risk of respiratory infections.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 10.04.2026

Active ingredient
Manufacturer
Techno Oncology
Dosage 100 mg
Dosage form Tablets
Tablets per pack 60
100% original product
Delivery across Ukraine
Customer reviews

What Customers Say

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00